EICHOR
● Active Not Recruiting
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Condition: Myelodysplastic Syndromes · Sponsor: Agios Pharmaceuticals, Inc.
About this study
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (45)
| Innovative Clinical Research Institute Whittier | Lakewood, California, United States | — |
| David Geffen School of Medicine at UCLA | Los Angeles, California, United States | — |
| Emad Ibrahim, MD, Inc. | Redlands, California, United States | — |
| Smilow Cancer Hospital at Yale New Haven | New Haven, Connecticut, United States | — |
| Mayo Clinic Jacksonville - PPDS | Jacksonville, Florida, United States | — |
| Edward H. Kaplan MD & Associates | Skokie, Illinois, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| Memorial Sloan Kettering Cancer Center | Long Island City, New York, United States | — |
| Duke Adult Blood and Marrow Clinic | Durham, North Carolina, United States | — |
| Monash Health, Monash Medical Centre | Clayton, Victoria, Australia | — |
| Ordensklinikum Linz GmbH Elisabethinen | Linz, Upper Austria, Austria | — |
| Fakultni nemocnice Ostrava | Ostrava, Czechia | — |
+ 33 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05490446